12 Oct The MIGHT Trial
The main purpose of this study/trial is to test whether patients with HMGCR myopathy can be safely and effectively treated with IVIG as their only medication for this condition.
Potential subjects must meet the following:
– Have a positive Anti-HMGCR antibody lab result within 12 months prior to enrollment
-Age 18 and older
-Demonstrate proximal muscle weakness
-Serum creatinine kinase (CK) more than 5 times the upper limit of normal
Leslie Lazar Thorn
Additional Study Details
Full Study Title
Monotherapy IVIG for HMG-CoA Reductase Auto-Antibody Positive Necrotizing Myopathy Treatment
James Andrews, MD
Accepts Healthy Volunteers?
University of Washington (Montlake)
1959 NE Pacific St
Seattle, Washington 98195